Drug Profile
HX 009
Alternative Names: anti-PD-1/CD47 infusion protein; HX-009; Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injectionLatest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Waterstone Hanxbio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Lymphoma